EP08.02-169 Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation

Abstract

Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation EGFR-TKI with proved efficiency and safety for untreated NSCLC patients with EGFR sensitizing mutations in China. The efficacy of the combination of first-generation EGFR-TKI and bevacizumab was confirmed by NEJ026, JO25567 ARTEMIS studies, but the effect of 3rd generation TKI plus bevacizumab is still under debate. This study was conducted to evaluate aumolertinib plus bevacizumab for untreated NS-NSCLC patients with EGFR sensitizing mutations.